The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2019 | Myeloma: pomalidomide, bortezomib and dexamethasone
Paul Richardson
• 3 Jun 2019
Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us about the results of a study investigating the use of pomalidomide, bortezomib and dexamethasone for the treatment of multiple myeloma. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
